Stock XVIVO XVIVO PERFUSION AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Real-time Estimate Cboe Europe
Other stock markets
 04:46:13 2024-04-25 am EDT 		5-day change 1st Jan Change
367.2 SEK -0.34% Intraday chart for Xvivo Perfusion AB +13.71% +10.77%
Apr. 24 Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest DJ
Apr. 24 Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 166.04 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
XVIVO PERFUSION AB Stock Xvivo Perfusion AB
+10.77% 1.07B
B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.89% 185B
C+
MEDTRONIC PLC Stock Medtronic plc
-2.43% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.10% 67.55B
A
DEXCOM, INC. Stock DexCom, Inc.
+11.10% 54.6B
B-
CENCORA, INC. Stock Cencora, Inc.
+15.86% 47.42B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.86% 42.24B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+9.55% 28.24B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+1.85% 26.42B
B
TERUMO CORPORATION Stock Terumo Corporation
+12.40% 25.66B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. XVIVO Stock
  4. Ratings Xvivo Perfusion AB